Guardant Health Stock Climbs As Wall Street Targets Surge

Guardant Health Inc. stocks have been trading up by 13.82 percent after upbeat cancer-detection data boosted investor optimism.

Live Update At 16:03:22 EDT: On Wednesday, July 01, 2026 Guardant Health Inc. stock [NASDAQ: GH] is trending up by 13.82%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Quick Financial Overview

Guardant Health is trading like a momentum name again. Over the recent stretch, GH climbed from a close near $124.89 on 2026/06/08 to about $170.77 on 2026/07/01. That is a powerful multi‑week trend, with higher lows building a clear uptrend channel on the daily chart.

Intraday action on the latest session shows steady demand. GH opened around $160.76, dipped briefly into the mid‑$150s, then grinded higher all day to finish near the highs. Late‑day five‑minute candles between 14:50 and the close show buyers in control, pushing GH from the high‑$160s into the $170s with only shallow pullbacks. For short‑term traders, that kind of closing strength usually signals dip‑buying interest for the next session.

More Breaking News

• Palantir Stock Pops As Nvidia AI Deal And Army Win Fuel Bullish Targets
• TC Stock Whipsaws As Token Cat Limited Tests Support
• PETS Stock Jumps As SilverCape Targets Takeover Amid Strain
• MSTR Jumps As New Capital Playbook Targets Buybacks, Liquidity

Fundamentally, Guardant Health is still a high‑growth, loss‑making story. Quarterly revenue came in around $301.7M, with trailing 12‑month revenue near $982.0M and roughly 30% annual growth over three and five years. Gross margin is strong at about 64.9%, but EBIT margin is roughly ‑39.8% and net losses remain heavy, with a recent quarter at about ‑$112.1M. The balance sheet carries long‑term debt around $1.68B, yet GH has solid liquidity: roughly $1.10B in cash and short‑term investments and a current ratio near 4.7. For traders, that mix says “aggressive growth, not yet profitable,” but with enough cash runway to keep funding expansion.

Why Traders Are Watching Guardant Health Now

Guardant Health is in the middle of a rare alignment: big regulatory win plus a full court press from Wall Street. The latest catalyst is the FDA approval of Guardant360 CDx as a companion diagnostic for Boehringer Ingelheim’s HERNEXEOS in HER2‑mutant advanced non‑small cell lung cancer. That approval is not just another headline. It marks the 27th companion diagnostic indication for the Guardant360 platform, embedding GH even deeper into routine precision oncology workflows.

When a liquid biopsy test like Guardant360 becomes the go‑to gatekeeper for a new targeted therapy, testing volumes tend to follow the drug’s uptake. Broad payer coverage already in place means more of those tests are reimbursed, which traders know can translate into durable revenue streams for Guardant Health. The premarket move of more than 1% on 2026/06/11 after the FDA news was an early tell that the market is assigning real value to this win.

At the same time, nearly every major bank on the Street is lining up behind GH. RBC Capital initiated Guardant Health with an Outperform and a Street‑high $185 target, specifically calling out the underpenetrated metastatic cancer testing market and Guardant360 Liquid CDx volume upside. Mizuho bumped its target to $175, tying the next phase of revenue growth and improving profitability to Guardant360 and Shield catalysts. Evercore ISI moved from In Line to Outperform and raised its target to $160, expecting an inflection in Guardant360 volumes and revenue from 2027 onward.

Goldman Sachs came in with a Buy and a $165 target, flagging GH as a leader in therapy selection on the back of a 740‑gene Guardant360 CDx panel, rising tissue‑based testing, and a coming tumor‑informed MRD product. Wolfe Research named Guardant Health its top idea in specialty diagnostics with a $150 target, while Bernstein and Guggenheim pushed targets to $175 and $160 after management meetings and improving sector fundamentals. For momentum traders, that stack of bullish calls around GH can fuel sustained rerating as long as news flow stays supportive.

There is a note of caution. Co‑CEO Helmy Eltoukhy sold about 100,000 shares (~$12.6M) on 2026/06/05, and director Musa Tariq sold roughly 1,951 shares later in the month. Those Form 4 filings are worth tracking, but both insiders still hold meaningful stakes, including around 2.0M shares indirectly for Eltoukhy. For most short‑term traders, the bigger focus remains on price, volume, and the catalyst pipeline rather than routine insider diversification.

Conclusion

Guardant Health is acting like a textbook catalyst runner backed by real fundamentals. GH has a powerful narrative: nearly $1.0B in annual revenue growing around 30% a year, high‑margin oncology testing, and now another FDA‑sanctioned role in guiding a branded targeted therapy. The company is not profitable yet, and margins are deeply negative, but cash on hand and strong gross margins give Guardant Health time to scale into its opportunity.

On the Street, the message is consistent. RBC’s $185 target, Bernstein’s $175, Mizuho’s $175, Goldman’s $165, Evercore’s $160, Guggenheim’s $160, and Wolfe’s $150 call all point in the same direction: expectations for higher volumes, better pricing, and eventual operating leverage. For traders, that wall of bullish research around GH often acts as a tailwind, especially when combined with a clean technical uptrend and fresh news flow. As Tim Bohen, lead trainer with StocksToTrade says, “I focus on momentum that’s visible right now. Speculation on future moves is outside my playbook.” That lens helps short‑term traders frame GH as a momentum and catalyst opportunity rather than a prediction game about distant scenarios.

Still, disciplined trading is key. Guardant Health is a volatile, high‑growth diagnostics name, not a sleepy blue chip. Earnings losses, leverage on the balance sheet, and insider sales can all spark sharp pullbacks. As Tim Sykes likes to remind traders, “The market doesn’t care about your opinion, it cares about catalysts, price action, and risk management—cut losses quickly and never fall in love with a stock.” Applied to GH, that means ride the trend while it’s working, respect your stops, and always treat this kind of research as educational context, not a trigger to blindly buy or sell.

This is stock news, not investment advice. StocksToTrade News delivers real-time stock market updates tailored to highlight the key catalysts driving short-term price movements. Our coverage is designed for active traders and investors who thrive in fast-moving markets, with a focus on volatile sectors like penny stocks, AI stocks, Robinhood stocks and other momentum plays. From earnings reports and FDA approvals to mergers, new contracts, and unusual trading volume, we break down the events that can spark significant price action.

Looking to level up your trading game? Explore StocksToTrade, the ultimate platform for traders. With powerful tools designed for swing and day trading, integrated news scanning, and even social media monitoring, StocksToTrade keeps you one step ahead.

Check out our quick startup guide for new traders!

• How to Read Stock Charts: A Guide for Beginners
• Trading Plan: 6 Steps to Create One
• How To Create a Stock Watchlist

Ready to build your watchlists? Check out these curated lists:

• AI Penny Stocks
• Robinhood Penny Stocks
• Top Biotech Stocks

Once your watchlist is set, take the next step and trade with confidence using StocksToTrade’s robust platform. Don’t miss out — grab your 14-day trial for just $7 and experience the edge you need to thrive in today’s fast-paced markets.